NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD)
Clinical trials for NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) explained in plain language.
Never miss a new study
Get alerted when new NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) trials appear
Sign up with your email to follow new studies for NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New syringe could simplify High-Dose eye treatment
Disease control CompletedThis study tested a pre-filled syringe containing a high dose (8 mg) of the drug aflibercept for two eye conditions: diabetic macular edema and wet age-related macular degeneration. The main goal was to see if retina specialists could prepare and inject the drug easily and safely…
Matched conditions: NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD)
Phase: PHASE3 • Sponsor: Regeneron Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 12:39 UTC
-
Could fewer injections control wet AMD? new study tests faricimab's staying power
Disease control CompletedThis study looked at 742 people newly diagnosed with wet age-related macular degeneration (nAMD) who received 3 monthly injections of faricimab (Vabysmo) instead of the usual 4. The goal was to see how long the effect lasted before another injection was needed. Researchers tracke…
Matched conditions: NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD)
Sponsor: Rigshospitalet, Denmark • Aim: Disease control
Last updated Jun 27, 2026 12:01 UTC
-
New eye drug brolucizumab tested in Real-World patients
Knowledge-focused CompletedThis completed study observed 572 patients with neovascular age-related macular degeneration or diabetic macular edema who were already receiving brolucizumab injections. Researchers collected routine medical data to see how well the drug resolved fluid in the eye and improved vi…
Matched conditions: NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD)
Sponsor: Novartis Pharmaceuticals • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:00 UTC